Milestone Scientific, Inc.
MLSS Healthcare Medical Instruments & Supplies
Milestone Scientific, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 3.99% from fiscal 2024. In the quarter to June 2026, revenue grew 22.3%, EPS grew 50.0%, free cash flow grew 66.7% and total debt fell 43.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow MLSS
Milestone Scientific, Inc. (MLSS) EV/Sales
As of 16 October 2026, Milestone Scientific, Inc. (MLSS) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 1.1× (June 2019) to 51.6× (March 2021); the current reading is higher than 19% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (71.34%) |
| FY2024 | 8.5× | 98.63% |
| FY2023 | 4.3× | 45.62% |
| FY2022 | 2.9× | (76.15%) |
| FY2021 | 12.3× | (43.90%) |
| FY2020 | 22.0× | 196.47% |
| FY2019 | 7.4× | 554.03% |
| FY2018 | 1.1× | (62.02%) |
| FY2017 | 3.0× | (0.56%) |
| FY2016 | 3.0× | (38.30%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | 9.78% |
| Mar 2026 | 2.7× | 11.92% |
| Dec 2025 | 2.4× | (40.43%) |
| Sep 2025 | 4.1× | (28.64%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| RVP Retractable Technologies, Inc. compare | −0.6× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| POCI Precision Optics Corp. compare | 0.9× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. | 3.1× |
| FEMY Femasys Inc. compare | 3.4× |
| NXGL NexGel, Inc. compare | 4.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)